Drug Patents owned by Nippon Shinyaku

1. List of Viltepso drug patents

VILTEPSO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10870676 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(8 years from now)

US9079934 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 12, 2025
Orphan Drug Exclusivity (ODE) Aug 12, 2027

Drugs and Companies using VILTOLARSEN ingredient

NCE-1 date: 2024-08-12

Market Authorisation Date: 12 August, 2020

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VILTEPSO family patents

15

United States

12

Japan

4

European Union

2

Spain

2

Croatia

2

Slovenia

2

Hungary

2

Poland

2

RS

2

Denmark

1

Portugal

1

Russia

1

San Marino

1

China

1

Taiwan, Province of China

1

Korea, Republic of

1

Lithuania

1

Canada

1

Cyprus

1

Australia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic